title: [Morbidity and mortality in HIV infection].
abstract: Combination antiretroviral therapy (cART) has dramatically improved the prognosis of HIV-infected individuals, with a close to a normal life expectancy in a significant proportion of treated individuals. Upon start of cART, HIV-induced immune deficiency can be prevented or, if already present, reconstituted. Remaining morbidity and mortality is partly due to the late diagnosis of HIV infection or late presentation of patients, when CD4-T-cells have already fallen below 200 cells/µl and/or AIDS-defining conditions have manifested. Further reasons for remaining morbidity and mortality are related to co-morbidities such as viral hepatitis and tumors, particularly in older patients. As HIV-infected patients become older, increasing co-morbidities and socio-economic costs may become a challenge in the future.
authors.affiliation: Klinik für Infektiologie und Spitalhygiene, Universitätsspital Basel, Petersgraben 4, 4031, Basel, Schweiz.
authors.forename: M
authors.initials: M
authors.lastname: Stöckle
authors.forename: L
authors.initials: L
authors.lastname: Elzi
authors.forename: J K
authors.initials: JK
authors.lastname: Rockstroh
authors.forename: M
authors.initials: M
authors.lastname: Battegay
mesh_terms: D004196:Disease Outbreaks / Q000517:prevention & control* / Q000706:statistics & numerical data*; D015658:HIV Infections / Q000401:mortality* / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D016019:Survival Analysis; D015996:Survival Rate